



CODEN [USA]: IAJ PBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES**Available online at: <http://www.iajps.com>

Research Article

**FORMULATION AND INVITRO EVALUATION OF FLOATING
MATRIX TABLETS OF MITIGLINIDE**Yenumula Nettekallu¹, Dr Rajesh Asija², Dr M. Purushothaman³¹ Dept of Pharmaceutics, Pratishta Institute of Pharmaceutical Sciences, Suryapet, Telangana.² Dept of Pharmaceutics, Maharshi Arvind Institute of Pharmacy, Mansarover Jaipur.³ Dept of Pharmaceutics, Scient Institute of Pharmacy, Ibrahimpatnam, RangaReddy**ABSTRACT:**

The floating matrix tablet of MITIGLINIDE (MTG) was prepared using the combination of release controlling polymer HPMC K15M and sodium alginate. The final optimization was done by applying 3² full factorial design, taking floating lag time (Flag), time to release 50% of drug (t₅₀) and time to release 90% of drug (t₉₀) as dependent factors. All the formulations were evaluated and results showed that M-3 formulation containing maximum amount of both variables gave promising results, hence was considered as optimized batch. A Gastroretentive multiparticulate system of MTG was developed as floating microsponges by quasi-emulsion solvent diffusion method. The primary screening of formulation related and process related variables was done by trial and error technique. The final optimization of dosage form was done by applying 3² full factorial design by taking concentrations of PVA (X₁) and EUDRGIT S 100 (X₂) as independent factors and product yield (Y₁), % entrapment efficiency (Y₂), % buoyancy (Y₃)

Key Words: Anti diabetic drug, mitiglinide, dissolution, Gastric retention.**Corresponding author:**

Yenumula Nettekallu,
Dept of Pharmaceutics,
Pratishta Institute of Pharmaceutical Sciences,
Suryapet, Telangana.

QR code



Please cite this article in press Yenumula Nettekallu et al., Formulation and in vitro Evaluation of Floating Matrix Tablets of Mitiglinide, Indo Am. J. P. Sci, 2017; 04(08).

1.INTRODUCTION

Meglitinide analog, Mitiglinide is a mildly acidic drug with the pKa 4.45. It remains unionized in acidic environment, hence gets absorbed from the stomach. Recently, it was found that mitiglinide is better absorbed via the stomach and the gastric absorption was delayed when the abdominal pH was higher than 5 pH [1,2]. Hence, it has a strong rationale for preparing the gastroretentive formulation to maintain the level of drug in the blood for improved treatment of type II diabetes mellitus.

In the present study, an attempt was made to prepare the floating matrix tablets of MTG by effervescence mechanism. The tablets were prepared using the combination of HPMC K15M with other ionic and anionic polymeric substances. The approach applied, was same as used for the formulation and optimization of floating matrix tablet of metformin. Various anionic and non-ionic polymers used in the present work are sodium alginate, Eudragit RLPO, Eudragit RSPO, xanthan gum and poloxamer 188.

2EXPERIMENTAL DETAILS

2.1 Method of Preparation of MTG Floating Matrix Tablets

Tablets containing 10mg of mitiglinide calcium dihydrate (MTG) were made by direct compression technique [6-8]. Using the ingredients and their quantities mentioned in table 1. The required quantity of drug, cross linking polymers (HPMC K15M and sodium alginate/Eudragit RLPO/ Eudragit RSPO/ xanthan gum/ poloxamer 188) and PVP K30 (dry binder) and gas generating agent (sodium bicarbonate), were sieved through sieve number #80 to break the lumps and also for proper blending of powder. The powder blends were thoroughly mixed in a mortar by following geometric order. Then, the required quantities of microcrystalline cellulose and magnesium stearate were added and the mixture was filled in plastic bottle. These bottles were placed in double cone

blender and the equipment was run for 1 minute. The powder blends were evaluated for pre-compression characteristics and finally the powder was compressed to prepare tablets, on rotary tablet compression machine using 7 mm round and flat punches with the hardness of 5 kg/sq.cm.

2.2 Preliminary Studies

Selection of a suitable polymer for the development of floating matrix drug delivery system is challenging. The polymer should have the capacity to make the tablet float over the gastric fluid. Moreover, it should be able to make a cohesive gel barrier and also possess the power to provide the controlled release of drugs [9]. The effervescent floating system is widely being used for developing floating matrix drug delivery system [10,11]. The matrices are made with gas generating agent, which in the presence of acidic environment, liberates carbon dioxide. Carbon dioxide gets entrapped in the gel forming hydrocolloid polymers, present in the formulation. This produces an upward motion of the dosage form and polymeric matrix maintains its buoyancy [12].


The release of the drug, from floating matrix tablet, is controlled by the entry of water into the matrices and ability of the polymer to form cohesive gel barrier. Hydroxy propyl methyl cellulose (HPMC) has been widely used to prepare the polymeric floating matrix systems. In present research work, formulations were prepared using HPMC K15M as release retarding and gel forming polymer. The quantity of the polymer was taken based on the previous studies carried out by the researcher and the available literature review [13,14]. The combination of HPMC K15M with other release retarding polymers (sodium alginate, Eudragit RLPO, Eudragit RSPO, xanthan gum, poloxamer 188), was tried for preparing floating matrix tablet of MTG. The composition of preliminary batches is given in table 6A.1. The prepared formulations were evaluated for post compression characteristics of floating gastroretentive matrix tablet.

TABLE 1 Composition (in mg) of preliminary batches of MTG Floating Matrix Tablets.

Sr No	Ingredients	MT1	MT2	MT3	MT4	MT5	MT6
1	MTG	10	10	10	10	10	10
2	PVP K30	10	10	10	10	10	10
3	HPMC K15M	50	50	50	50	50	50
4	Sodium bicarbonate	25	25	25	25	25	25
5	Sodium Alginate	30	-	-	-	-	-
6	Eudragit RSPO	-	-	30	-	-	-
7	Xanthan gum	-	-	-	30	-	-
8	Poloxamer188	-	-	-	-	30	-
9	MCC	23.5	23.5	23.5	23.5	23.5	23.5
10	Mg stearate	1.5	1.5	1.5	1.5	1.5	1.5

2.3 Drug Excipient Compatibility Study [15]

There is always the possibility of drug polymer interaction in any formulation. To check any such kind of interaction, Fourier-transform infrared spectroscopy (FTIR) study was conducted. The FTIR of pure drug (MTG), polymers (HPMC K15M and sodium alginate) and optimized formulation of MTG floating matrix tablet were taken. The pure drug, polymer and physical mixture were separately mixed with IR grade KBr. This mixture was then scanned over a wave number range of 4000 to 400 cm^{-1} .



3. RESULTS AND DISCUSSION

3.1 Preliminary Studies

The gastroretentive floating matrix tablet of MTG was prepared with HPMC K15M as release retarding polymer in combination with other polymers. The effect of the polymer blend was checked on the floatation characteristics of the tablets and also on the release pattern of the drug from the matrix.

The effect of the physical evaluation of the prepared dosage forms is presented in table 5A.4. All the formulations, except MT5 complied with the weight

variation study. Formulation MT5, prepared with HPMC K15M and Poloxamer 188 was forming flakes during the punching, hence did not pass the weight variation study. Hardness of all the batches was found to be in the range of 4.8 - 5.4 kg/cm^2 except for MT5, which was bending during the h to 100.86%. The minimum drug content was observed in the tablet containing poloxamer 188. The friability was found to be less than 0.5% that complies the limits given in IP (Table 5A.4). Hardness testing. The drug content in all the batches was found to be in the range of 89.43%

TABLE 2: Results of preliminary batches of MTG gastroretentive floating matrix tablets

Batch code	Weight variation	Hardness* (kg/cm ²)	Drug content* (%)	Friability* (%)	Lag Time*(s)	Floating Time*(h)
MT1	Complies	4.9±0.35	99.32±1.74	0.28±0.17	30.43 ± 2.87	> 12
MT2	Complies	5.2±0.73	100.86±1.65	0.27±0.39	15.76 ± 1.72	3
MT3	Complies	5.4±0.23	100.73±1.43	0.13±0.10	15.34 ± 3.43	8
MT4	Complies	4.8±0.29	100.31±0.98	0.39±0.07	20.76 ± 3.87	10
MT5	Doesn't Comply	bending not breaking	89.43±2.87	0.15±0.03	22.64 ± 2.97	> 12
MT6	Complies	5.3±0.36	99.53±1.78	0.24±0.06	120.4 ± 4.71	> 12

3.3 *In vitro* Floatation Studies

The *in vitro* floating lag time of all the formulations was found to be in the range of 15.34±3.43 to 120.4±4.71 seconds. The formulation MT6, prepared with only HPMC K15 M, had the maximum floating lag time, probably because of delayed gel layer formation due to slow hydration of the polymer. All other formulations had reasonably same floating lag time.

The floatation time of all the formulations was found to be ranging from 3 hours to 12 hrs, which means that the polymers had significant effect on the floating time of tablets. The unanticipated results obtained was in the formulation MT2, prepared with HPMC K15M and Eudragit RLPO. The formulation disintegrated within 3 hours, hence could not float. Formulation MT3, prepared with HPMC K15M and Eudragit RSPO could float for only 8 hours. Moreover, the tablets were sinking on and off during the study duration, which may be because Eudragit RSPO was not able to get hydrated and swell properly. Formulations, MT1 (prepared with HPMC K15M and sodium alginate), MT5 (prepared with HPMC K15M and xanthan gum) and MT6 (prepared with only HPMC K15M), gave maximum floating time of 12hrs. Overall, it was apparent from the buoyancy studies that the presence of other release retarding polymer in combination with HPMC K15M had a drastic effect on the floatation behavior of formulations, as indicated in Table 5A.4. The pictorial representation of *in vitro* floatation behavior of preliminary batches of MTG floating matrix tablets is shown in figure 2.1.

3.4 Drug Release Studies of Preliminary Batches

The release study of the preliminary batches of MTG floating matrix tablet, prepared with combination of polymers was performed. The release study was conducted in 500ml of 0.1N HCl under all the standard conditions prescribed by Indian Pharmacopoeia (IP).

At regular intervals the samples of the dissolution fluid were withdrawn and analyzed by high performance liquid chromatography (HPLC). The sink condition was maintained in the dissolution apparatus by replacing the withdrawn dissolution fluid with fresh 0.1N HCl. The tabulated release from the preliminary batches is given in table 1 and the graphical representation of the same is given in Figure 2.

The results of *in vitro* drug release studies of MTG matrix tablet were different than the findings of floating matrix tablet of metformin, prepared using same polymer combination. This change can be attributed to the properties of drug, for which the formulation is developed. Results of formulation MT2 (formulation with HPMC K15M and Eudragit) were totally opposite to that of findings of chapter 4, where this combination of polymers showed the best floating and sustained release characters. Antagonistically, in present study, this polymer blend could not withstand the conditions of dissolution medium and got dissolved completely after first hour of drug release study. After, rigorous literature search, the reason for such findings was understood. Such outcome was probably because of the salt form of the mitoglinide, the presence of calcium ions was responsible for this result. The literature supporting the finding has been given during the discussion of floatation studies of the same batches.

Formulation MT3 was prepared with HPMC K15M and Eudragit RSPO as literature supported the release retarding property of Eudragit RSPO [1]. During the present study the formulation could sustain the release of the drug till 7 hours. This outcome may be attributed to the gelling capacity of release retarding polymer, as the literature suggests that difference in the release pattern of the drug is because of the type and amount of the adjuvants [32]. At our experimental concentration of polymers, the MT3 could not sustain the release beyond the said duration.


TABLE 5A.5 *In vitro* drug release data of preliminary batches of floating matrix tablets of MTG*

Time (hrs)	MT 1 (%)	MT 2 (%)	MT 3 (%)	MT 4 (%)	MT 5 (%)	MT 6 (%)
0	0	0	0	0	0	0
1	14.23 ± 1.53	45.47 ± 3.54	10.32 ± 2.89	17.43 ± 1.04	11.03 ± 1.93	12.43 ± 1.54
2	15.78 ± 2.92	96.32 ± 2.71	26.34 ± 1.59	25.98 ± 1.11	14.44 ± 1.99	15.43 ± 1.03
3	33.1 ± 2.79	100.43 ± 3.04	32.99 ± 2.91	41.49 ± 2.43	33.43 ± 2.73	28.43 ± 1.19
4	38.37 ± 1.49	-	63.97 ± 3.17	53.36 ± 2.71	31.54 ± 1.08	34.54 ± 0.73
5	44.54 ± 1.32	-	84.24 ± 1.06	62.29 ± 1.04	34.75 ± 2.45	39.57 ± 0.57
6	58.2 ± 1.6	-	96.43 ± 3.79	84.55 ± 3.77	43.64 ± 0.88	43.91 ± 3.09
7	64.41 ± 1.18	-	100.43 ± 0.75	93.43 ± 2.46	46.34 ± 1.53	54.54 ± 2.67
8	75.32 ± 2.17	-	-	100.54 ± 1.91	55.65 ± 0.92	67.34 ± 1.12
10	83.32 ± 0.92	-	-	-	61.62 ± 2.21	75.32 ± 1.18
12	91.32 ± 0.89	-	-	-	64.32 ± 0.79	82.43 ± 1.68

* n=3, average of three determinations ± SD

Formulation, MT4, prepared with HPMC K15M and xanthan gum gave the sustained release of the drug for 8 hours. The sustained release effect of the combination was better than observed for floating matrix tablets MH in chapter 4. The findings might be due to the interaction of xanthan gum with calcium ions present in the drug. The literature

gave the mixed review, some studies ascertained that calcium ions increase the release of the drug from the xanthan gum matrix and some researchers suggests that the release of the drug from the matrix, made by xanthan gum, is delayed in presence of calcium ions [13].



4. CONCLUSION:

The floating matrix tablets of MTG were prepared by direct compression technique. The preliminary batches were prepared using HPMC K15M, as release retarding polymer along with other ionic and anionic polymeric substances. The prepared formulations were evaluated for floatation behavior and drug release. The results revealed that tablets prepared using HPMC K15M and sodium alginate, as release retarding polymers were giving satisfactory sustained release property and acceptable floatation behavior. Hence, the final optimization of floating MTG formulation was done by applying 3^2 full factorial design using sodium alginate and HPMC K15M as independent variable. The floating lag time (F_{lag}), time to release 50% of drug (t₅₀) and time to release 90% of drug (t₉₀) were taken as dependent factors. The design was employed and evaluated using the Design-Expert® Software (version- 9.0.6, Stat-Ease) by running 9 experiments. All the formulations were evaluated for their physical properties, *in vitro* buoyancy studies and drug release study. Results showed that M-3 formulation containing maximum amount of both variables released the MTG for the period of 12hrs and was falling in the yellow region of overlay plot. Hence, it was considered as optimized gastroretentive floating matrix tablet of MTG. The radiographic study of the barium sulphate loaded tablets of this optimized formula, confirmed the gastroretention of the developed formulation

5. REFERENCES:

- 1.Arya, P. and Pathak, K., 2014. Assessing the viability of microsponges as gastro retentive drug delivery system of curcumin: Optimization and pharmacokinetics. *International Journal of Pharmaceutics*, 460(1), pp.1-12.
- 2.Nokhodchi, A., Jelvehgari, M., Siah, M.R.,

- Mozafari, M., 2007. Factors affecting themorphology of benzoyl peroxide microsponges. *Micron*, 38, pp.834-840.
- 3.Singh, R.P. and Prajapati, S.K., 2014. Formulation and Evaluation of Prednisolone loaded Microsponges for Colon Drug Delivery: in-vitro and Pharmacokinetic study. *International Journal of Pharmaceutical Sciences and Research*, 5(5), p.1994.
- 4.Karthika, R., Elango, K., Ramesh Kumar, K. and Rahul, K., 2013. Formulation and evaluation of lornoxicam microsponges tablets for the treatment of arthritis. *International Journal of Pharmaceutical Innovations*, 3(2), p.29.
- 5.Jain, V. and Singh, R., 2011. Design and characterization of colon-specific drug delivery system containing paracetamol microsponges. *Archives of Pharmaceutical Research*, 34(5), pp.733-740.
- 6.<https://www.drugs.com/monograph/metformin-hydrochloride.html>
- 7.https://pubchem.ncbi.nlm.nih.gov/compound/Metformin_hydrochloride#section=Top
- 8.<https://www.fda.gov/ohrms/dockets/dailys/02/may02/053102/800471e6.pdf>
- 9.Japanese Pharmacopoeia 2016. Society of Japanese Pharmacopoeia. *Seventeenth Edition (JP XVII) pp.* 1258-1259.
- 10.Jin, L. and Cao, Q., 2012. Effect of gemfibrozil on the pharmacokinetics of mitiglinide in rats. *Arzneimittelforschung*, 62(01), pp.40-45.
- 11.<https://pubchem.ncbi.nlm.nih.gov/compound/6918235>
- 12.<https://www.drugbank.ca/salts/DBSALT001868>
- 13.Mitiglinide Calcium Hydrate. *Drugs of the Future*, 25(10), pp.1034-1042.
- 14.Mikoshiha, I., Suzuki, H. and Kiyono, Y., 2003. *Drug composition for Blood Sugar*